Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea.
- Author:
Osung KWON
1
;
Jung Min AHN
;
Do Yoon KANG
;
Se Hun KANG
;
Pil Hyung LEE
;
Soo Jin KANG
;
Seung Whan LEE
;
Young Hak KIM
;
Cheol Whan LEE
;
Seong Wook PARK
;
Duk Woo PARK
;
Seung Jung PARK
Author Information
- Publication Type:Original Article
- Keywords: Absorbable implants; Bioresorbable vascular scaffolds; Percutaneous coronary intervention
- MeSH: Absorbable Implants; Acute Coronary Syndrome; Chungcheongnam-do; Coronary Artery Disease*; Coronary Vessels*; Drug-Eluting Stents; Endovascular Procedures; Follow-Up Studies; Hospitalization; Humans; Korea*; Male; Percutaneous Coronary Intervention; Stents; Thrombosis; Tomography, Optical Coherence; Ultrasonography
- From:The Korean Journal of Internal Medicine 2018;33(5):922-932
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Compared with metallic drug-eluting stents (DES), bioresorbable vascular scaffolds (BVS) may further improve long-term outcomes of percutaneous coronary intervention (PCI) in patients with coronary artery disease. We report our early experience with BVS in Korea. METHODS: We evaluated 105 consecutive patients with BVS implanted at Asan Medical Center, Korea between October 21, 2015 and June 3, 2016. Angiographic results, and in-hospital and 6-month clinical outcomes were assessed. RESULTS: A total of 134 BVS were implanted to treat 115 lesions. The mean age was 62 ± 10.5 years; 85 patients (81%) were males, 26 patients (25%) were presented with acute coronary syndrome. Among 115 lesions treated with BVS, 76 (66.1%) were B2/C type, 27 (23.5%) were bifurcation lesions, and four (3.5%) were chronic total occlusion. Pre-dilation and post-dilation using high-pressure non-compliant balloon was performed in 104 lesions (90.4%) and 113 lesions (98.2%), respectively. During the procedure, intravascular imaging was used for all patients (100%; intravascular ultrasound 89 and optical coherence tomography 40 patients). Device success rate was 100%. In-segment and in-scaffold acute again were 1.1 ± 0.6 and 1.3 ± 0.5 mm, respectively. Periprocedural myocardial infraction occurred in four patients (3.8%). No deaths, stent thrombosis, or urgent revascularizations occurred either during hospitalization or the follow-up period. CONCLUSIONS: In this single-center experience, implantation of BVS with intravascular imaging support was feasible and early clinical outcomes were excellent. Evaluation of long-term efficacy and safety of BVS and its feasibility in clinical use for a broader range of lesions is warranted.
